7 апр. 2024 г. · In this randomised, placebo-controlled, double-blind clinical trial, patients aged 18 years or older with an acute coronary syndrome who ...

7 апр. 2024 г. · The ULTIMATE-DAPT placebo-controlled, double-blind trial showed that, in patients with an acute coronary syndrome treated with percutaneous ...

8 мая 2024 г. · To assess whether the use of ticagrelor alone, compared with ticagrelor plus aspirin, could reduce the incidence of clinically relevant bleeding events.

7 апр. 2024 г. · Ticagrelor monotherapy following one month of dual antiplatelet therapy (DAPT) outperforms 12-month DAPT (aspirin and ticagrelor) post PCI ...

7 апр. 2024 г. · The aim of this trial was to assess whether the use of ticagrelor alone, compared with ticagrelor plus aspirin, could reduce the incidence of ...

27 окт. 2024 г. · The ULTIMATE-DAPT trial showed that compared with standard 12-month DAPT with aspirin and ticagrelor, 1-month DAPT followed by de-escalation ...

7 апр. 2024 г. · Dropping aspirin and continuing ticagrelor as soon as 1 month after PCI for ACS patients is as effective as continuing dual antiplatelet therapy (DAPT) over a ...

7 апр. 2024 г. · The Ultimate-DAPT trial has several limitations: 1) The primary efficacy endpoint included minor bleeding (BARC type 2), however, major bleeding ...

The ULTIMATE-DAPT trial was designed to test whether antiplatelet monotherapy with ticagrelor alone vs. ticagrelor plus aspirin reduces the incidence of ...

The ULTIMATE-DAPT is a multicenter, randomized, double-blind, placebo-controlled trial that compared ticagrelor from 1 month after drug-eluting coronary stent ...